Northern Trust
KTTA icon

Northern Trust’s Pasithea Therapeutics KTTA Stock Holding History

Northern Trust’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2K Buy
31,405
+12,033
+62% +$8.28K ﹤0.01% 4389
2026
Q1 		$14.4K Sell
19,372
-8,718
-31% -$7.29K ﹤0.01% 4355
2025
Q4 		$36.2K Buy
+28,090
New +$24.7K ﹤0.01% 4334
2024
Q1 		– Sell
-2,354
Closed -$17.4K – 4451
2023
Q4 		$17.4K Buy
+2,354
New +$17.5K ﹤0.01% 4379

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Northern Trust's KTTA Position: Q2 2026 in Review

Northern Trust increased its Pasithea Therapeutics (KTTA) stake by 62% in Q2 2026, buying an estimated $8.28K and bringing the position to 31,405 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4389.

Northern Trust first reported a position in KTTA in Q4 2023 and has held it in 4 quarters since. The position peaked at $36.2K in Q4 2025. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Northern Trust held 31,405 shares of Pasithea Therapeutics worth $16.2K as of Q2 2026.
  • Northern Trust bought 12,033 Pasithea Therapeutics shares in Q2 2026, an estimated $8.28K.
  • Pasithea Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4389 holding.
  • Northern Trust first reported a position in Pasithea Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Northern Trust's Pasithea Therapeutics position peaked at $36.2K in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.